gMendel
Chris Kyriakidis is an accomplished executive with extensive experience in marketing, brand management, and strategic development across various industries, including MedTech and consumer goods. Currently serving as the CEO and Co-Founder of gMendel®, a company specializing in AI-driven diagnostic services for genetic disorders, Chris is also a Board Member at Quaternity, focusing on sustainable technologies and behavioral changes. Previous roles include Co-founder and Strategic Advisor at Besesaka, where impactful changes in children's lives in Ghana were pursued through education and boxing, and Brand Strategist at Right to Dream, which aims to redefine excellence in educational institutions. Chris's career includes significant roles at GN Hearing A/S, ALK, and Novo Nordisk, where strategies and initiatives led to substantial growth and market positioning improvements. Educational credentials include an MBA from Erasmus University and a Ph.D. in Chemistry from the University of Amsterdam.
This person is not in any teams
gMendel
AI-powered, vertically-integrated IVD certified technology for accurate, fast and affordable diagnosis of genetic disorders & beyond. There are 350 million people worldwide suffering from >10,000 genetic disorders / rare diseases, but <500 of these diseases have an approved treatment. The societal burden of the rare diseases exceeds €2 trillion, demonstrating an apparent unmet clinical need for better, faster & affordable Companion Diagnostics of rare diseases towards precision treatments. Today, the diagnosis of rare diseases, that takes on average 7 years, is based on the current sequencing technologies, has a high cost and complexity and leaves many patients undiagnosed. gMendel® is the only end-to-end cloud based technology that uses AI for accurate, fast & affordable diagnosis of multiple rare diseases & beyond. Moreover, gMendel®’s technology is automated, transcending the need for bioinformatician’s intervention, reducing the experimental errors & costs. This improves accessibility and has a potential to revolutionize genetic analysis without any change to current health care protocols. Compared to current available technologies in the market, our novel combination of genomics & AI makes our technology better, faster, and more affordable than any other in the companion diagnostics market. In 2022, gMendel® obtained CE mark under EU IVDD, becoming the world’s first IVD certified technology for human genetic disorders utilizing long read sequencing technology and AI. gMendel® has achieved Proof of Concept to detect deletions, insertions, point mutations by doing whole exome sequencing or DNA region customisation by amplicons or probes. We are currently in the process to commercialise our technology for Companion Diagnostics for Anemia, Epilepsy, Cystic Fibrosis & Spinal Muscular Atrophy.